subscribe
 

Agreement for CRISPR engineered cell lines

14th August 2018


Oxford Genetics has secured a multi-million pound contract with a leading multi-billion dollar global ecommerce provider of reagents and tools to the research and clinical community.

As part of the agreement, Oxford Genetics will leverage its high throughput automated genomic engineering platform for CRISPR modification of mammalian cell lines.

Ryan Cawood, CEO said, "This contract highlights our commitment to providing the highest quality cell line engineering services to our global customer base and continuing to add value to their operations. We have moved away from manual processing, which is the norm in this market, in favour of automated, scalable platforms. 

"This approach means we are well positioned to deliver the large number of custom-engineered cell lines per year that the global market is forecast to need. 

"We are excited about this project, which will see us significantly expand our product portfolio and continue to deliver innovative products and solutions to the pharmaceutical industry."





Subscribe

 

Subscribe



Newsbrief

Twitter Icon © Setform Limited
subscribe